- Conditions
- Partial Thickness Rotator Cuff Tears
- Interventions
- TPX-115, Cryopreserving hyaluronic acid medium, Saline
- Biological · Other · Drug
- Lead sponsor
- Tego Science, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- La Mesa, California • Deerfield Beach, Florida • Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2233–2256
of 33,216
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bilateral Nasal Polyposis
- Interventions
- Fluticasone propionate
- Drug
- Lead sponsor
- Optinose US Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 10
- States / cities
- Stockton, California • Centennial, Colorado • Louisville, Kentucky + 7 more
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
- Interventions
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 24
- States / cities
- Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
- Conditions
- Scleroderma, Systemic
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CS-917, metformin hydrochloride, pioglitazone
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- FDC tiotropium / salmeterol, Placebo, Salmeterol, Tiotropium (Spiriva®)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 20
- States / cities
- Boulder, Colorado • Wheat Ridge, Colorado • Winter Park, Florida + 16 more
- Conditions
- HIV I Infection
- Interventions
- Vacc-4x, Sterile water
- Drug
- Lead sponsor
- Bionor Immuno AS
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Sacramento, California • Miami, Florida + 1 more
- Conditions
- Tourette Syndrome in Children, Tourette Syndrome in Adolescence
- Interventions
- T92, Placebo
- Dietary Supplement
- Lead sponsor
- Tasly Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- HIV Infection, Bone Loss, Osteopenia, Osteoporosis
- Interventions
- Zoledronic acid
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 30 Years to 50 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Pompe Disease
- Interventions
- Clenbuterol, Placebo
- Drug
- Lead sponsor
- Dwight Koeberl, M.D., Ph.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Psoriasis
- Interventions
- PPC-06 400 mg QD, PPC-06 400 mg BID, PPC-06 600 mg, Placebo
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited, India
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 74
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 54 more
- Conditions
- Vitamin A Deficiency
- Interventions
- Vitamin A supplement, Placebo
- Dietary Supplement
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 19 Years to 30 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- COVID-19
- Interventions
- PF-07321332, Ritonavir, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 78
- States / cities
- Pelham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more
- Conditions
- Asthma
- Interventions
- Placebo MDPI, Albuterol MDPI
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Costa Mesa, California + 30 more
- Conditions
- Inflammation
- Interventions
- resveratrol, Placebo Comparator: Sugar Pill
- Dietary Supplement · Other
- Lead sponsor
- Marywood University
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Scranton, Pennsylvania
- Conditions
- Microvascular Obstruction
- Interventions
- Temanogrel, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Long Beach, California • Palo Alto, California • Chicago, Illinois
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Severe Asthma
- Interventions
- GB-0895, Placebo
- Drug
- Lead sponsor
- Generate Biomedicines
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 786 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 37
- States / cities
- Northridge, California • Pasadena, California • Rancho Cucamonga, California + 32 more
- Conditions
- Endothelial Dysfunction, Oxidative Stress
- Interventions
- Creatine monohydrate, Placebo
- Dietary Supplement
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Tallahassee, Florida
- Conditions
- Rheumatoid Arthritis
- Interventions
- etanercept, Placebo, DMARD Therapy
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more
- Conditions
- Multiple Sclerosis
- Interventions
- dalfampridine ER, placebo
- Drug
- Lead sponsor
- Brown, Theodore R., M.D., MPH
- Individual
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Kirkland, Washington
- Conditions
- Dermatitis, Atopic
- Interventions
- Bermekimab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more
- Conditions
- Acute Bronchiolitis
- Interventions
- 3% Hypertonic Saline, 0.9 % normal saline
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 2 Months to 12 Months
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Radiation Induced Oral Mucositis
- Interventions
- Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Placebo, Intensity-Modulated Radiation Therapy, Cisplatin
- Drug · Radiation
- Lead sponsor
- Galera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 55 more